查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008679

肺炎治療市場：2026年至2032年全球市場預測（依治療方法、給藥途徑、病患年齡層、病原體、通路和適應症分類）

Pneumonia Therapeutics Market by Therapy Type, Route Of Administration, Patient Age Group, Pathogen Type, Distribution Channel, Indication Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肺炎治療市場價值將達到 181.9 億美元，到 2026 年將成長至 198.8 億美元，到 2032 年將達到 368 億美元，複合年成長率為 10.59%。

主要市場統計數據
基準年 2025 181.9億美元
預計年份：2026年 198.8億美元
預測年份 2032 368億美元
複合年成長率 (%) 10.59%

為相關人員提供關於正在重新定義肺炎治療格局的臨床、監管和商業趨勢的全面策略概述。

本報告整合了最新的臨床趨勢、監管變化和不斷演進的醫療服務模式，闡明了肺炎治療的現狀，這些因素正在重新定義相關人員的優先事項。分析概述了影響研究挑戰、產品開發策略和病患管理路徑的關鍵促進因素，同時重點闡述了科學創新與醫療保健系統需求之間的交集。

識別科學創新、醫療服務模式和報銷環境方面的變革性變化，這些變化正在加速整個肺炎治療流程的變革。

科學、醫療服務和資金籌措的變革性變化正在為肺炎治療的創新開闢新的途徑。生物製藥和免疫調節療法的進步正在拓展傳統抗感染藥物以外的治療選擇，而對病原體和宿主反應更精準的理解則推動了更具針對性的研發策略。同時，醫療服務也變得更加分散化。門診治療、居家氧氣療法和遠距監測正在減輕住院患者的負擔，並改變治療方法的選擇和實施方式。

分析 2025 年美國對肺炎治療藥物徵收關稅措施的累積經濟、供應鏈和臨床取得影響。

美國2025年實施的關稅調整的累積影響將對肺炎治療的供應鏈、籌資策略和臨床取得途徑產生多方面的影響。進口原料、呼吸設備組件或成品藥關稅的提高可能導致生產成本上升，並擠壓擁有全球分散供應鏈的製造商的利潤空間。這種壓力往往迫使製造商採取成本削減措施，例如供應商多元化、關鍵組件近岸外包以及重新談判供應商契約，以維持生產的連續性和產品的價格競爭力。

關鍵細分洞察揭示了治療方法類型、給藥途徑、分銷管道、患者年齡層、病原體特徵和適應症類別之間的相互作用。

一套精細的細分框架揭示了治療差異化和商業性機會如何跨越治療方法類型、給藥途徑、分銷管道、患者年齡層、病原體類型和適應症等要素相互交織。治療方法類型包括輔助性治療（如皮質類固醇和霧化器）；感染疾病物（包括抗生素、抗真菌藥物和抗病毒藥物，其中抗生素細分為Aminoglycosides、BETA-內醯胺類、大環內酯類、奎諾酮和四環黴素）；生物製藥（包括免疫調節劑和單克隆抗體）；以及以氧療、機械通氣和氧氣療法治療為中心的輔助治療。這些區分至關重要，因為作用機制、安全性以及所需的臨床環境決定了治療方法在從急性護理到門診護理的連續過程中所處的位置。

深入分析美洲、歐洲、中東和非洲以及亞太地區如何塑造臨床實踐、進入途徑和創新重點。

區域趨勢顯著影響著美洲、歐洲、中東和非洲以及亞太地區的臨床實踐模式、治療藥物的可及性以及創新療法的採納順序。在美洲，醫療保健系統和支付方生態系統優先考慮臨床療效和成本效益的證據，鼓勵採用療效已證實且具有顯著經濟價值的療法。此外，特定市場的過渡期照護模式和門診環境正在加速吸入和口服藥物的推廣應用，從而實現早期出院和居家照護。

重點介紹領先的肺炎治療研發公司的策略定位、產品線差異化、合作夥伴關係和商業化策略。

在企業層面，發展趨勢不再只取決於單一產品的上市，而是更重視產品線差異化、策略夥伴關係和商業化敏捷性。授權協議和聯合開發夥伴關係常被用於最佳化臨床應用路徑，並加速取得快速診斷和吸入給藥平台等互補技術，從而縮短產品上市時間。將標靶抗感染疾病項目與輔助生物製藥製劑結合的研發公司，能夠滿足多樣化的臨床需求，同時建構多條展現價值的途徑。

為行業領導者提供切實可行的策略建議，以最佳化肺炎治療的臨床開發、供應彈性、報銷談判和患者獲取途徑。

產業領導者必須推動一系列切實可行且影響深遠的舉措，以在保持藥品可及性和可負擔性的同時，持續推動創新。首先，將衛生經濟學終點指標和真實世界數據（REW）收集納入臨床開發項目，並使其與支付方的證據要求保持一致，將簡化報銷談判流程，並加速在各種醫療環境中的推廣應用。其次，透過供應商多元化、確保區域生產能力和策略性庫存管理來增強供應鏈韌性，將降低貿易中斷和物流延誤對藥品和醫療設備供應的影響。

透明的調查方法，描述了肺炎治療評估中使用的資料來源、檢驗方法、相關人員訪談和分析框架。

本研究採用多方面方法，結合與關鍵相關人員的對話、整合二手文獻以及反覆檢驗，以確保獲得可靠且可操作的見解。資料來源包括已發表的臨床文獻、監管指導文件、醫療設備和治療方法的技術摘要、不同醫療保健系統的採購政策以及揭示公司策略行動的公開文件。透過對臨床醫生、醫院採購負責人、生命週期管理專家和銷售經理的結構化訪談收集關鍵訊息，從而獲得有關營運挑戰和產品推廣促進因素的具體背景資訊。

一項綜合分析，旨在為參與肺炎治療藥物研發和推廣的相關人員確定策略挑戰、風險緩解策略和機會途徑。

總之，本分析整合了各項研究結果，並提出了一系列策略挑戰，旨在指南各組織在肺炎治療領域實現以患者為中心的永續解決方案。在供應鏈和貿易逆風的情況下，必須將對標靶治療和支持性護理的投資與切實可行的運作策略相結合，以維持治療的可及性。同時，獲得強力的證據來證明其臨床和經濟價值，將是促進其在不同醫療機構中廣泛應用的關鍵因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療方法分類的肺炎治療市場

  • 輔助性治療
    • 皮質類固醇
    • 噴霧器
  • 抗感染藥物
    • 抗生素
      • Aminoglycosides
      • BETA-內醯胺
      • 大環內酯類
      • 奎諾酮
      • 四環黴素
    • 抗真菌藥物
    • 抗病毒藥物
  • 生物製藥
    • 免疫調節劑
    • 單株抗體
  • 支持性護理
    • 點滴管理
    • 人工呼吸
    • 氧氣療法

第9章 肺炎治療市場：依給藥途徑分類

  • 吸入
  • 靜脈注射
  • 口服

第10章：依患者年齡層分類的肺炎治療藥物市場

  • 成人版
  • 老年人
  • 兒童

第11章 以病原體分類的肺炎治療藥物市場

  • 非典型
    • 衣原體
    • 退伍軍人菌
    • 黴漿菌
  • 細菌
  • 真菌
  • 病毒性的

第12章 肺炎治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 肺炎治療藥物市場（依適應症分類）

  • 社區傳播
  • 院內感染
  • 人工呼吸器相關

第14章 肺炎治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 肺炎治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 肺炎治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國肺炎治療市場

第18章：中國肺炎治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Allergan plc
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biobrick Pharma
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Lincoln Pharmaceuticals Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Mankind Pharma Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus UK Limited by CSL Limited
  • Serum Institute of India
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Wellona Pharma
  • Zydus Healthcare Limited
Product Code: MRR-8E22B61932B6

The Pneumonia Therapeutics Market was valued at USD 18.19 billion in 2025 and is projected to grow to USD 19.88 billion in 2026, with a CAGR of 10.59%, reaching USD 36.80 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.19 billion
Estimated Year [2026] USD 19.88 billion
Forecast Year [2032] USD 36.80 billion
CAGR (%) 10.59%

Comprehensive strategic introduction to the evolving clinical, regulatory, and commercial dynamics that are redefining pneumonia therapeutics for stakeholders

The introduction establishes the current state of pneumonia therapeutics through a synthesis of contemporary clinical developments, regulatory shifts, and evolving delivery models that are redefining stakeholder priorities. This narrative frames the principal drivers shaping research agendas, product development strategies, and patient management pathways while emphasizing the intersection of scientific innovation and healthcare system needs.

By situating therapeutic advances alongside changing care environments, this opening analysis clarifies how new mechanisms of action, adjunctive care approaches, and supportive technologies are influencing clinical decision making. It also highlights the crucial role of cross-functional collaboration among clinicians, payers, manufacturers, and supply chain partners in converting scientific promise into improved patient outcomes. Transitioning from a descriptive baseline, the introduction sets up subsequent sections to explore structural shifts, regulatory and trade pressures, segmentation nuances, regional dynamics, and strategic responses that will determine near-term trajectories for pneumonia therapeutics.

Identification of transformative shifts in scientific innovation, care delivery models, and reimbursement landscapes that are accelerating change across pneumonia therapeutic pipelines

Transformative shifts across science, care delivery, and financing are converging to create new pathways for innovation in pneumonia therapeutics. Advances in biologics and immune modulation are expanding therapeutic options beyond traditional anti-infectives, while the precision characterization of pathogens and host responses is driving more targeted development strategies. At the same time, care delivery is decentralizing: outpatient management, home oxygen and remote monitoring reduce inpatient burden and change how therapies are chosen and delivered.

Concurrently, payer and reimbursement models increasingly reward clinical outcomes and value-based approaches, which pressures developers to demonstrate differentiated benefits beyond pathogen clearance. Digital health tools and real-world evidence are being integrated into regulatory and reimbursement dialogues, accelerating adaptive trial designs and post-approval evidence generation. As a result, scientific innovation, care model evolution, and financing mechanisms are collectively reshaping prioritization across discovery, clinical development, and commercialization, requiring integrated strategies that balance efficacy, access, and economic sustainability.

Analysis of the cumulative economic, supply chain, and clinical access implications stemming from United States tariff actions in 2025 for pneumonia therapeutics

The cumulative effects of tariff adjustments enacted by the United States in 2025 create a multi-dimensional impact on pneumonia therapeutic supply chains, procurement strategies, and clinical access pathways. Increased duties on imported raw materials, components for respiratory devices, or finished pharmaceuticals can raise production costs and compress margins for manufacturers whose supply chains are globally distributed. This pressure often prompts cost mitigation responses such as supplier diversification, nearshoring of critical components, and renegotiation of supplier contracts to preserve manufacturing continuity and product affordability.

Beyond direct cost effects, tariffs can alter logistics and lead times for critical inputs such as APIs, single-use device components, and specialized medical equipment used in oxygen therapy and mechanical ventilation. These disruptions have downstream clinical implications when hospitals and procurement teams encounter variability in availability or elevated pricing that affects formulary decisions and stocking policies. Moreover, tariff-driven changes incentivize stronger supplier qualification processes, increased inventory buffers, and strategic stockpiling for critical items. In parallel, payers and health systems may intensify scrutiny of total cost of care, accelerating shifts toward therapeutics and delivery models that demonstrate durable clinical and economic value. In aggregate, the 2025 tariff dynamics pressure manufacturers to redesign supply networks and strengthen commercial arguments for value and access while health systems adapt procurement strategies to maintain clinical readiness.

Critical segmentation insights revealing how therapy types, administration routes, distribution channels, patient age cohorts, pathogen profiles, and indication categories interact

A nuanced segmentation framework illuminates where therapeutic differentiation and commercial opportunity intersect across therapy type, administration route, distribution channel, patient age group, pathogen type, and indication. Therapy type spans adjunctive therapies that include corticosteroids and device-based nebulizers, anti-infectives composed of antibiotics, antifungals, and antivirals with antibiotics further detailed into aminoglycosides, beta lactams, macrolides, quinolones, and tetracyclines, biologics that encompass immune modulators and monoclonal antibodies, and supportive therapies oriented around fluid management, mechanical ventilation, and oxygen therapy. These distinctions matter because mechanism of action, safety profiles, and required clinical settings determine where a therapy sits along the acute care to outpatient continuum.

Route of administration-covering inhalation, intravenous, and oral delivery-directly affects adherence, ease of outpatient management, and the complexity of supply logistics. Distribution channels ranging from hospital pharmacy to online and retail pharmacy shape go-to-market approaches, pricing strategies, and patient access pathways. Patient age groups, including adult, geriatric, and pediatric cohorts, demand tailored safety and dosing strategies and influence trial design and labeling priorities. Pathogen type segmentation, which includes atypical organisms subdivided into Chlamydophila, Legionella, and Mycoplasma, as well as bacterial, fungal, and viral causes, drives diagnostic requirements and targeted therapeutic development. Finally, indication type such as community acquired, hospital acquired, and ventilator associated pneumonia creates distinct clinical management algorithms, differing regulatory expectations, and variable pathways to adoption. Collectively, this segmentation matrix provides a roadmap for aligning R&D focus, clinical trial populations, and commercialization plans with unmet needs and operational realities.

In-depth regional insights on how Americas, Europe Middle East and Africa, and Asia-Pacific are each shaping clinical practice, access pathways, and innovation priorities

Regional dynamics exert a strong influence on clinical practice patterns, access to therapeutics, and the sequencing of innovation adoption across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems and payer ecosystems emphasize evidence of clinical benefit and cost-efficiency, which incentivizes therapeutics with demonstrable outcomes and robust economic value propositions. Transitional care models and outpatient capabilities in certain markets also accelerate adoption of inhaled and oral regimens that facilitate earlier discharge and home-based care.

Europe, Middle East & Africa present heterogenous regulatory and reimbursement landscapes where centralized guidelines coexist with national-level variations in uptake and procurement. This mosaic drives the need for flexible regulatory strategies, regionally tailored clinical evidence packages, and differentiated pricing approaches. Asia-Pacific encompasses a spectrum from highly sophisticated healthcare markets to rapidly developing systems where access, local manufacturing capacity, and public health priorities shape adoption. Across these regions, differences in pathogen prevalence, diagnostic infrastructure, and hospital capacity influence the relative demand for biologics, targeted anti-infectives, and supportive technologies. Taken together, these regional characteristics require companies to deploy tailored regulatory engagement, supply planning, and evidence generation strategies that align with local clinical practices and procurement frameworks.

Key company-level insights outlining strategic positioning, pipeline differentiation, collaborative ventures, and commercialization strategies across leading pneumonia therapeutics developers

Company-level dynamics are increasingly defined by a focus on pipeline differentiation, strategic partnerships, and commercialization agility rather than singular product launches. Developers that combine targeted anti-infective programs with adjunctive biologic approaches position themselves to address heterogeneous clinical needs while creating multiple levers for value demonstration. Licensing agreements and co-development partnerships are commonly used to accelerate access to complementary technologies, such as rapid diagnostics or inhalation delivery platforms, that strengthen clinical adoption pathways and improve time-to-market execution.

At the commercial interface, companies are investing in evidence generation beyond pivotal trials, emphasizing real-world data collection, health economics and outcomes research, and post-authorization safety monitoring to meet payer and clinician expectations. Manufacturing strategies are evolving to incorporate dual-sourcing and regional production capacity for critical inputs and devices to mitigate supply interruptions. Finally, corporate strategies increasingly reflect a blend of selective M&A to secure complementary capabilities, targeted geographic expansion to capture access opportunities, and flexible commercial models that support hospital procurement teams and community providers in diverse settings.

Actionable strategic recommendations for industry leaders to optimize clinical development, supply resilience, reimbursement engagement, and patient access for pneumonia care

Industry leaders must pursue a set of pragmatic, high-impact actions to sustain innovation while safeguarding access and affordability. First, aligning clinical development programs with payer evidence requirements by embedding health economic endpoints and real-world evidence collection into trial designs will facilitate reimbursement discussions and accelerate uptake in diverse healthcare settings. Second, strengthening supply chain resilience through supplier diversification, regional manufacturing capacity, and strategic inventory management will reduce vulnerability to trade disruptions and logistic delays that affect both drug and device availability.

Third, companies should cultivate integrated partnerships with diagnostics providers and care delivery organizations to enable precision targeting of therapies and to support outpatient and home-based care models. Fourth, commercial strategies must balance tiered pricing and contracting flexibility with transparent value communication to hospitals, payers, and pharmacy channels. Fifth, embedding digital tools for adherence support, remote monitoring, and patient engagement can improve outcomes and create measurable value for health systems. By implementing these coordinated actions, organizations can simultaneously advance clinical innovation, reinforce access pathways, and create defensible commercial positions in a fragmented and rapidly evolving therapeutic landscape.

Transparent research methodology explaining data sources, validation approaches, stakeholder interviews, and analytical frameworks employed in assessing pneumonia therapeutic areas

This research employed a multi-method approach combining primary stakeholder engagement, secondary literature synthesis, and iterative validation to ensure robust, actionable insights. Data sources included published clinical literature, regulatory guidance documents, device and therapeutic technical briefs, procurement policies from diverse health systems, and public filings that illuminate strategic company behavior. Primary inputs were gathered through structured interviews with clinicians, hospital procurement specialists, lifecycle management experts, and commercial leaders who provided contextual detail on operational challenges and adoption drivers.

Analytical frameworks integrated qualitative thematic analysis with scenario mapping to identify risk factors and opportunity pathways across clinical, supply chain, and reimbursement dimensions. A validation layer reconciled conflicting signals by triangulating interview findings with documented regulatory precedents and technical specifications of devices and drug classes. Throughout the process, emphasis was placed on transparency in assumptions, traceability of evidence, and the reproducibility of key conclusions, ensuring that recommendations are grounded in observable practice and validated stakeholder perspectives.

A concluding synthesis that distills strategic imperatives, risk mitigations, and opportunity pathways for stakeholders engaged in pneumonia therapeutic development and delivery

The conclusion synthesizes the analysis into a set of strategic imperatives that guide organizations toward durable, patient-centered solutions in pneumonia therapeutics. Investment in targeted therapeutics and supportive care modalities must be paired with pragmatic operational strategies that preserve access amid supply chain and trade headwinds. Simultaneously, robust evidence generation that demonstrates clinical and economic value will be decisive in achieving broad adoption across varied care settings.

Risk mitigation requires proactive supply chain redesign, stronger partnerships across diagnostics and care delivery, and adaptable commercial approaches that respect regional heterogeneity. Opportunity lies in integrating diagnostics-driven therapeutics, expanding outpatient care capabilities, and leveraging digital health to enhance adherence and monitoring. Collectively, these imperatives form a coherent agenda for stakeholders seeking to advance therapeutic innovation while ensuring that clinical gains translate into measurable improvements in patient outcomes and health system performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumonia Therapeutics Market, by Therapy Type

  • 8.1. Adjunctive Therapies
    • 8.1.1. Corticosteroids
    • 8.1.2. Nebulizers
  • 8.2. Anti Infectives
    • 8.2.1. Antibiotics
      • 8.2.1.1. Aminoglycosides
      • 8.2.1.2. Beta Lactams
      • 8.2.1.3. Macrolides
      • 8.2.1.4. Quinolones
      • 8.2.1.5. Tetracyclines
    • 8.2.2. Antifungals
    • 8.2.3. Antivirals
  • 8.3. Biologics
    • 8.3.1. Immune Modulators
    • 8.3.2. Monoclonal Antibodies
  • 8.4. Supportive Therapies
    • 8.4.1. Fluid Management
    • 8.4.2. Mechanical Ventilation
    • 8.4.3. Oxygen Therapy

9. Pneumonia Therapeutics Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral

10. Pneumonia Therapeutics Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Pneumonia Therapeutics Market, by Pathogen Type

  • 11.1. Atypical
    • 11.1.1. Chlamydophila
    • 11.1.2. Legionella
    • 11.1.3. Mycoplasma
  • 11.2. Bacterial
  • 11.3. Fungal
  • 11.4. Viral

12. Pneumonia Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Pneumonia Therapeutics Market, by Indication Type

  • 13.1. Community Acquired
  • 13.2. Hospital Acquired
  • 13.3. Ventilator Associated

14. Pneumonia Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Pneumonia Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Pneumonia Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Pneumonia Therapeutics Market

18. China Pneumonia Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Allergan plc
  • 19.7. AstraZeneca PLC
  • 19.8. Aurobindo Pharma Limited
  • 19.9. Bayer AG
  • 19.10. Biobrick Pharma
  • 19.11. Cipla Limited
  • 19.12. Dr. Reddy's Laboratories Ltd.
  • 19.13. Eli Lilly and Company
  • 19.14. F. Hoffmann-La Roche Ltd.
  • 19.15. GlaxoSmithKline PLC
  • 19.16. Hikma Pharmaceuticals PLC
  • 19.17. Lincoln Pharmaceuticals Ltd.
  • 19.18. Lupin Pharmaceuticals, Inc.
  • 19.19. Mankind Pharma Ltd.
  • 19.20. Merck & Co., Inc.
  • 19.21. Novartis AG
  • 19.22. Pfizer Inc.
  • 19.23. Sanofi S.A.
  • 19.24. Seqirus UK Limited by CSL Limited
  • 19.25. Serum Institute of India
  • 19.26. Sun Pharmaceutical Industries Ltd.
  • 19.27. Teva Pharmaceutical Industries Ltd.
  • 19.28. Viatris Inc.
  • 19.29. Wellona Pharma
  • 19.30. Zydus Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMONIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 250. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 251. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 252. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 253. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 254. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 258. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 289. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 290. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 291. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 292. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 293. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 295. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 297. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 302. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 303. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 304. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 305. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 306. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 308. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 310. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD